Melanoma vaccine data drive Moderna stock volatility before results

Published on 10/27/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman Sachs raised its target to USD 137 from USD 120 on October 23, 2026. Moderna stock costs EUR 174.59, 0.27 percent above the Xetra close.

Melanoma data and earnings dates

Moderna's melanoma vaccine data triggered a sell-off exceeding 17 percent on October 22, 2026.
Second-quarter revenue reached USD 145.0 million, while 2026 revenue growth guidance stayed at up to 10 percent.
Moderna stock trades at EUR 174.59 at 11:46 a.m. CET at Lang & Schwarz on October 27, 2026, 0.27 percent above the Xetra close of October 26, 2026.
Moderna is scheduled to report third-quarter results on November 6, 2026, before the US market opens.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) was trading at EUR 174.59 at Lang & Schwarz on October 27, 2026, at 11:46 a.m. CET, 0.27 percent above the Xetra close of October 26, 2026, at EUR 174.12. The stock remains tied to investor scrutiny of late-stage melanoma vaccine data released ahead of a cancer conference, while third-quarter results are approaching.

According to Yahoo Finance on October 23, 2026, Moderna stock extended losses after details from the personalized melanoma vaccine trial circulated early. The stock had fallen more than 17 percent on October 22, 2026, while more than USD 17.0 billion in market value disappeared in that session.

Q2 revenue and guidance

Moderna's second-quarter revenue was USD 145.0 million, up 2.00 percent from the same quarter of 2025, while its net loss narrowed to USD 782.0 million from USD 825.0 million. The figures came from the company's Q2 2026 earnings materials summarized by Perplexity Finance.

Management reiterated 2026 revenue growth of up to 10 percent and projected year-end cash and investments of USD 4.7 billion to USD 5.2 billion. The same update lowered projected cost of sales to USD 1.7 billion and research and development expense to USD 2.9 billion, with a USD 0.9 billion litigation settlement charge included in cost of sales.

What comes before the results?

Goldman Sachs raised its Moderna price target to USD 137 from USD 120 on October 23, 2026, while keeping a Neutral rating, according to Yahoo Finance. Morgan Stanley retained a Neutral view with a USD 95 target, and Citi maintained a Sell rating with a USD 80 target, showing a wide gap between analyst views and the market price.

Three dated stock events

On August 1, 2026, Moderna announced positive phase 3 results for its personalized cancer vaccine, according to Yahoo Finance. On October 22, 2026, the stock fell more than 17 percent as trial details circulated. On October 23, 2026, the stock closed down more than 1 percent as investors assessed the data.

Next reporting date

MarketBeat lists November 6, 2026, before the market opens, as Moderna's next third-quarter reporting date. Its consensus calls for revenue of USD 891.34 million and a loss of USD 1.11 per share, compared with USD 1.02 billion revenue and a USD 0.51 loss per share in the year-earlier quarter.

Price stays below the yearly high

Moderna's Xetra quote had a 52-week range of EUR 19.37 to EUR 222.10 and a market capitalization of EUR 71.0 billion as of October 26, 2026. The current euro price is therefore below the reported yearly high, while the upcoming results and clinical-data response remain the next measurable company-specific checkpoints.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.